Groups | Drug Treatment | Paw thickness in mm | % Inhibition at 3 h | ||||||
---|---|---|---|---|---|---|---|---|---|
0 h | ½ h | 1 h | 1½ h | 2 h | 2½ h | 3 h | |||
I | Control 0.1% CMC | 1.8 ± 0.02 | 3.6 ± 0.02 | 5.2 ± 0.04 | 6.2 ± 0.02 | 5.4 ± 0.02 | 4.8 ± 0.02 | 4.1 ± 0.02 | - |
II | Indomethacin 20 mg/kg | 1.6 ± 0.04 | 2.4 ± 0.04** | 2.9 ± 0.01** | 3.2 ± 0.01** | 2.8 ± 0.01** | 2.5 ± 0.04** | 2.0 ± 0.01* | 48 |
III | ME 200 mg/kg | 1.1 ± 0.02 | 2.8 ± 0.04** | 3.2 ± 0.04** | 3.6 ± 0.04** | 3.3 ± 0.02** | 2.9 ± 0.02* | 2.5 ± 0.01** | 42 |
IV | ME 400 mg/kg | 1.4 ± 0.04 | 2.6 ± 0.01** | 3.1 ± 0.01** | 3.4 ± 0.03** | 3.0 ± 0.01** | 2.6 ± 0.01** | 2.2 ± 0.01** | 45 |
V | CE 200 mg/kg | 1.4 ± 0.02 | 3.4 ± 0.01* | 4.0 ± 0.02** | 4.4 ± 0.04** | 3.6 ± 0.02** | 3.1 ± 0.02** | 2.6 ± 0.03** | 29 |
VI | CE 400 mg/kg | 1.2 ± 0.01 | 2.9 ± 0.02** | 3.4 ± 0.02* | 3.8 ± 0.02** | 3.2 ± 0.04** | 2.9 ± 0.04** | 2.5 ± 0.02* | 39 |
VII | LF 100 mg/kg | 1.5 ± 0.03 | 3.0 ± 0.03** | 3.1 ± 0.01** | 3.1 ± 0.01** | 2.7 ± 0.01** | 2.2 ± 0.02** | 1.8 ± 0.03** | 50 |